Drugmaker Stocks Could See Tailwind From U.S. Midterm Elections

Gridlock in Congress for at least the next two years would lessen the risk of disruptive, government-dictated pricing changes, according to analysts.On the flip side, a Democratic sweep would be likely to shift the focus to drug manufacturers and away from the rebates drug companies earn from selling their products to federal health plans.Large-cap pharma stocks have rallied since the summer as investors searched for safety from trade tensions.